إعلان
إعلان
KYMR
Kymera Therapeutics, Inc. Common Stock
72.72
USDبرعاية
-5.09
-6.55%
٠٢ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
72.61
-0.10
-0.14%
تقارير أرباح KYMR
النسبة الإيجابية المفاجئة
KYMR تفوق 6 من 21 آخر التقديرات.
29%
التقرير التالي
بيانات التقرير القادم
٢٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$15.47M
/-$0.81
التغير الضمني من Q3 25 (Revenue/ EPS)
+459.71%
/-13.83%
التغير الضمني من Q4 24 (Revenue/ EPS)
+109.23%
/-7.95%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On ٠٤ نوفمبر ٢٠٢٥, KYMR reported earnings of -0.94 USD per share (EPS) for Q3 25, missing the estimate of -0.82 USD, resulting in a -14.63% surprise. Revenue reached 2.76 مليون, compared to an expected 19.33 مليون, with a -85.70% difference. The market reacted with a +0.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 25 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 15.47 مليون USD, implying an decrease of -13.83% EPS, and increase of 459.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.94, missing estimates by -14.63%, and revenue of $2.76M, -85.7% below expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.32%, changed from $59.72 before the earnings release to $59.91 the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٢٥ فبراير ٢٠٢٦.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 25
analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $15.47M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان